Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease.

Stevens WW, Sun J, Castillo JP, Braciale TJ.

Viral Immunol. 2009 Jul;22(4):243-51. doi: 10.1089/vim.2009.0016.

3.

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

Olson MR, Varga SM.

J Immunol. 2007 Oct 15;179(8):5415-24.

4.

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

Castilow EM, Olson MR, Varga SM.

Immunol Res. 2007;39(1-3):225-39. Review.

PMID:
17917067
6.

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.

Johnson TR, Rothenberg ME, Graham BS.

J Leukoc Biol. 2008 Sep;84(3):748-59. doi: 10.1189/jlb.0907621. Epub 2008 Jun 2.

8.

Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM.

J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.

9.

Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Olson MR, Varga SM.

J Immunol. 2009 Mar 1;182(5):3024-31. doi: 10.4049/jimmunol.0803585.

10.

CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.

Zhang L, Li H, Hai Y, Yin W, Li W, Zheng B, Du X, Li N, Zhang Z, Deng Y, Zeng R, Wei L.

J Virol. 2017 Apr 28;91(10). pii: e02111-16. doi: 10.1128/JVI.02111-16. Print 2017 May 15.

11.

Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.

Su YC, Townsend D, Herrero LJ, Zaid A, Rolph MS, Gahan ME, Nelson MA, Rudd PA, Matthaei KI, Foster PS, Dent L, Tripp RA, Lee J, Simson L, Mahalingam S.

J Virol. 2015 Feb;89(3):1564-78. doi: 10.1128/JVI.01536-14. Epub 2014 Nov 19.

12.
13.

Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.

Srinivasa BT, Fixman ED, Ward BJ.

Eur J Immunol. 2014 Aug;44(8):2349-59. doi: 10.1002/eji.201344206. Epub 2014 Jun 5.

14.
15.

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.

Vaccine. 2007 Jul 20;25(29):5378-89. Epub 2007 May 24.

PMID:
17561317
16.

Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.

Spender LC, Hussell T, Openshaw PJ.

J Gen Virol. 1998 Jul;79 ( Pt 7):1751-8.

PMID:
9680139
17.

CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness.

Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Hamelmann E, Gelfand EW.

J Immunol. 1999 Apr 1;162(7):4207-11.

18.

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.

Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW.

PLoS One. 2011;6(7):e21823. doi: 10.1371/journal.pone.0021823. Epub 2011 Jul 15.

19.

Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.

Helson R, Olszewska W, Singh M, Megede JZ, Melero JA, O'Hagan D, Openshaw PJ.

Vaccine. 2008 Feb 6;26(6):753-61. doi: 10.1016/j.vaccine.2007.12.006. Epub 2007 Dec 26.

Supplemental Content

Support Center